Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany: Final results of the phase 2 multicohort INGE-B trial

A prospective, multicenter, multicohort phase 2 trial evaluated the efficacy and safety of first-line palbociclib and letrozole or first-line and later-line palbociclib and fulvestrant in patients with advanced HR+ HER2- breast cancer. The researchers found that palbociclib and letrozole or first- or later-line fulvestrant showed good efficacy and tolerability, which aligns with previous results from the PALOMA trial.